亿胜生物(01061.HK):复宏汉霖(02696.HK)许可产品将在多国开展三期临床研究
亿胜生物(01061.HK)公布,就与复宏汉霖(02696.HK)共同开发渗出性(湿性)老年性黄斑部病变治疗许可产品,重组抗血管内皮生长因子人源化单克隆抗体眼用注射液HLX04-O的开展临床试验申请,近期已获拉脱维亚国家药物署批准,三期、全球及多中心临床研究拟於近期启动,该研究将於包括中国、澳大利亚、俄罗斯联邦、新加坡、西班牙及波兰在内的国家/地区开展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.